Pharma Products

Strategic collaborations played a crucial role in AstraZeneca's achievements, particularly in enhancing diagnostic capabilities and treatment outcomes

Investments worth Rs 25,813 crore have been made and 56,171 new jobs were added as of September this year under the production-linked incentive scheme for pharmaceuticals, the government said on Friday. In its year-end review, the Department of Pharmaceuticals (DoP) also said the 'Pradhan Mantri Bhartiya Janaushadhi Pariyojana' achieved its target of opening 10,000 retail outlets in 2023 to provide quality generic medicines at affordable prices to the poor and underprivileged. The production-linked incentive (PLI) scheme for pharmaceuticals is being implemented with an objective of enhancing India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector. The total outlay of the scheme is Rs 15,000 crore and the scheme duration is from 2020-2021 to 2028-29, an official statement said. Under the Scheme, 55 applicants have been selected, which includes five applicants

Dr Reddy's Laboratories on Wednesday said its unit has inked a licensing agreement with Coya Therapeutics Inc to develop a combination therapy for the treatment of amyotrophic lateral sclerosis (ALS). Dr Reddy's Laboratories SA and Coya have entered into a development and license agreement for the development and commercialisation of COYA 302, an investigational combination therapy for ALS, the Hyderabad-based drugmaker said in a statement. As per the terms of the agreement, Coya has granted Dr Reddy's an exclusive licence to commercialise COYA 302 in the US, Canada, the European Union and the UK for ALS. Coya retains the right to commercialise COYA 302 in Japan, Mexico, and each country in South America. As per the agreement, Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA 302 for patients with ALS in the US. As per the deal, Dr Reddy's will make a USD 7.5 million upfront payment to Coya. Upon the first FDA ...

Canada-based Apotex Inc has sought USD 118.14 million from Panacea Biotec over breach of a collaboration agreement inked in 2014, the capital-based drug firm said on Thursday. The company has received a notification dated October 4 from the International Court of Arbitration, Paris, intimating that an arbitration proceeding has been initiated as per a request by Apotex Inc, Panacea Biotec said in a regulatory filing. Apotex has alleged that the company has breached its obligations under the collaboration agreement for research, development, licence, supply and sale of products inked on May 9, 2014, it added. Apotex has alleged that there has been a purported delay in seeking approval from US Food and Drug Administration for the product mentioned in the said agreement, Panacea Biotec said. "Apotex has claimed USD 118.14 million towards outsized alleged losses plus interest thereon to the extent permissible under the applicable law," it added. The company believes it is not in breac

Zisavel capsules will be available as 100 mg capsules and will be priced at Rs 7,992 for 7 capsules

The UCPMP is voluntary and there is no legal penalty for violating the code

As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

In an interview, Arun Chandravarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda

The company had posted a consolidated net profit of Rs 265.47 crore in the corresponding period last fiscal, Ipca Laboratories said in a regulatory filing

Firm says it has been in talks with at least eight buyers, including a few overseas companies, to supply the anti-retroviral drug

'Not storing the drug properly can lead to the drug becoming spurious,' official said